Loading stock data…
EMBC
$3.12-0.29 (-8.50%)
Market ClosedLast close May 13
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Embecta Corp. in the Healthcare sector is trading at $3.12. Wall Street consensus targets $8.00 (2 analysts), implying a +156.4% move over the next 12 months. The stock is currently near its 52-week low of $3.11, remaining 72.6% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. Risk note: RSI 10 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +156.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 10) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$3.12
Potential Upside
241.1%
Whystock Fair Value$10.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Hold
Mean target$8.00+156.4%
Range$5.00 – $11.00
Fundamentals
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection device...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$545.41M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
3.90
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.10
Div Yield
Strong income play. Yield provides a meaningful total return floor.
651.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.75%
Volume
Today's trading volume
4.84M
Recent News
S&P Global Ratings Cuts Credit Rating on Embecta (EMBC) After Revenue Decline
Embecta Corp. (NYSE:EMBC) is included among the 12 Best Micro-Cap Dividend Stocks to Buy Now. On May 12, S&P Global Ratings lowered its issuer credit rating on Embecta Corp. (NYSE:EMBC) to ‘B’ from ‘B+’. The agency pointed to weaker operating performance, increasing competitive pressure, and softer-than-expected fiscal 2026 guidance. It also downgraded the company’s senior […]
Why Embecta's (NASDAQ:EMBC) Earnings Are Better Than They Seem
The stock was sluggish on the back of Embecta Corp.'s ( NASDAQ:EMBC ) recent earnings report. Along with the solid...
Embecta Corp. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Embecta Corp. ( NASDAQ:EMBC ) shares in the week since it released its second-quarter...
Embecta (EMBC): Do Buybacks Amid Losses Reveal Capital Discipline or Strategic Uncertainty?
Embecta Corp. recently reported second-quarter 2026 results showing sales of US$221.8 million and a net loss of US$4.1 million, and also approved a quarterly dividend of US$0.0100 per share payable on June 15, 2026. At the same time, the company authorized a new three-year share repurchase program of up to US$100 million, signaling management’s willingness to return capital to shareholders even as quarterly performance softened versus the prior year. We’ll now examine how Embecta’s new...
Why Embecta Stock Plummeted Today
Embecta's most recent quarterly report didn't give investors much to be exicited about.